Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Oct 25:12:1062921.
doi: 10.3389/fonc.2022.1062921. eCollection 2022.

Editorial: New strategies to tackle chemoresistance in cancer

Carmela De Marco  1   2 , Maura Sonego  3 , Anna Martina Battaglia  1   2 , Giuseppe Viglietto  1   2 , Flavia Biamonte  1   2
Affiliations
Editorial

Editorial: New strategies to tackle chemoresistance in cancer

Carmela De Marco et al. Front Oncol. .
No abstract available

Keywords: FBXW7; cancer; cell cycle inhibitors; chemoresistance; ferroptosis; immune escape; miR-506-3p.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The figure highlights the topics covered in the research articles included in this special issue. The articles provide a detailed overview of five important topics in tackling chemoresistance in cancer: targeting cyclin-dependent kinases (A); targeting immune escape (B); targeting miR-506/RAD17 axis (C); targeting ferroptosis (D); protein FBXW7 factor (E). Adapted from “New strategies for treating cancer” by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates.
See this image and copyright information in PMC

Comment on

  • Editorial on the research topic New strategies to tackle chemoresistance in cancer

References

    1. Ward RA, Fawell S, Floc’h N, Flemington V, McKerrecher D, Smith PD. Challenges and opportunities in cancer drug resistance. Chem Rev (2021) 121:3297–351. doi: 10.1021/ACS.CHEMREV.0C00383 - DOI - PubMed
    1. Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Therapy resistance: Opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer 2022 22:6 (2022) 22:323–39. doi: 10.1038/s41568-022-00454-5 - DOI - PMC - PubMed
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71:209–49. doi: 10.3322/CAAC.21660 - DOI - PubMed
    1. Biamonte F, Santamaria G, Sacco A, Perrone FM, di Cello A, Battaglia AM, et al. . MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer. Sci Rep (2019) 9:1–12. doi: 10.1038/s41598-019-42221-x - DOI - PMC - PubMed
    1. Mignogna C, Staropoli N, Botta C, de Marco C, Rizzuto A, Morelli M, et al. . Aurora kinase a expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. J Ovarian Res (2016) 9:1–8. doi: 10.1186/S13048-016-0238-7/FIGURES/4 - DOI - PMC - PubMed

Publication types

LinkOut - more resources